Please use this identifier to cite or link to this item:
|Title:||Busulfan is effective second-line therapy for older patients with Philadelphia-negative myeloproliferative neoplasms intolerant of or unresponsive to hydroxyurea||Authors:||Forsyth, Cecily J ;Douglas, G.;Harrison, C.N.;Bennett, M.;Stevenson, W.S.;Hounsell, J.;Ratnasingam, S.;Ritchie, D.;Ross, D.M.;Grigg, A.||Affliation:||Central Coast Local Health District
|Issue Date:||Jan-2017||Source:||58(1):89-95||Journal title:||Leukemia & lymphoma||Department:||Haematology||Abstract:||Hydroxyurea (Hu) is widely used as first-line cytoreductive therapy for patients with high-risk Philadelphia-negative myeloproliferative neoplasms (Ph-neg MPN), but a small proportion of patients have refractory disease or experience adverse effects. Studies have demonstrated busulfan (Bu) to be an active first-line agent, but data on its role as second-line or later therapy are minimal. To evaluate its efficacy and safety in this context, we undertook a multicenter audit of Ph-neg MPN patients who had received Bu as therapy for Hu intolerance or failure. Of 51 patients identified, 38 (75%) achieved either complete or partial hematological response following at least one Bu cycle. Bu was generally well tolerated, with only 21/135 (15%) cycles complicated by adverse effects, predominantly cytopenia; only 6% of cycles were ceased due to treatment complications. Bu is an effective and well-tolerated agent in patients with Ph-neg MPN in the setting of Hu intolerance or unresponsiveness.||URI:||https://elibrary.cclhd.health.nsw.gov.au/cclhdjspui/handle/1/1066||DOI:||10.1080/10428194.2016.1187269||Pubmed:||https://www.ncbi.nlm.nih.gov/pubmed/27454522||ISSN:||1026-8022||Publicaton type:||Journal Article||Keywords:||Drug Therapy|
|Appears in Collections:||Haematology|
Show full item record
checked on Jan 30, 2023
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.